**Abstract**

To obtain insight into abnormalities in neurodevelopmental trajectories of schizophrenia, analyses of patient-derived human induced pluripotent stem cells (hiPSCs) should be informative. Given the extreme complexity and heterogeneity of genomic architecture underlying 'general schizophrenia', analyses of schizophrenia patients with the 22q11.2 deletion could be beneficial because the deletion is one of the highest risk factors. We established hiPSCs from two schizophrenia patients with the 22q11.2 deletion and three controls. Neurosphere size, neural differentiation efficiency, neurite outgrowth and neurogenic-to-gliogenic competence ratio were significantly reduced in the patient-derived cells. As an underlying mechanism, we focused on the role of *DGCR8*, a key gene for microRNA (miRNA) processing and mapped in the deleted region. In mice, *Dgcr8* hetero-knockout is known to show a similar phenotype of reduced neurosphere size. miRNA profiling detected reduced expression levels of miRNAs belonging to miR-17/92 cluster and miR-106a/b in the patient-derived neurospheres. Those miRNAs are reported to target p38α, and conformingly the levels of p38α were up-regulated in the patient-derived cells. p38α is known to drive gliogenic differentiation. Inhibition of p38 activity by SB203580 in patient-derived neurospheres partially restored neurogenic competence. Furthermore, we confirmed an elevated expression of *GFAP*, a gliogenic (astrocyte) marker, in postmortem brains from schizophrenia patients. These results suggest that a dysregulated balance of neurogenic and gliogenic competences may underlie 'general' schizophrenia.
